Skip to main content
Top

08-06-2024 | Gastrointestinal Stromal Tumor | Hollow Organ GI

An ultrasound based method for predicting the malignant potential of primary gastrointestinal stromal tumors preoperatively

Authors: Tingting Li, Juan Li, ZiYue Hu, Man Lu

Published in: Abdominal Radiology

Login to get access

Abstract

Objective

Gastrointestinal stromal tumors (GISTs) are difficult to identify the risk level accurately without surgical pathological confirmation. The purpose of our study was to propose a noninvasive prediction method for predicting the malignant potential of GISTs preoperatively by using contrast-enhanced ultrasound (CEUS) with gastric distention.

Methods

We reviewed 47 GISTs who underwent CEUS from April 2017 to August 2023 retrospectively, all the lesions were certificated by pathology after surgery. The age of the patient, size of the lesion, shape, necrosis, calcification in the lesion, perfusion parameters including arrival time (AT), peak intensity (PI), time to peak (TTP), and area under the curve (AUC) of the lesion and surrounding normal tissue were analyzed. Logistic regression analyses were performed. Of the 47 GISTs, 26 were high-risk and 21 low-risk tumors respectively.

Results

Compared with low-risk GISTs, high-risk GIST had faster AT (7.7s vs. 11.5s, p < 0.05), higher PI (15.2dB vs. 12.5dB, p < 0.05), and larger size (4.4 cm vs. 2.2 cm, p < 0.001). In multivariate logistic regression, AT, PI, and size were significant features. The corresponding regression equation In (p/(1-p)=-5.9 + 4.5 size + 4.6 PI + 4.0 AT).

Conclusion

The size, AT, and PI of the GISTs on CEUS can be used as parameters for a noninvasive risk level prediction model of GISTs. This model may help identify the different risk levels of GISTs before surgery.
Literature
1.
go back to reference Miettinen M, Lasota J. Gastrointestinal stromal tumors–definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. VIRCHOWS ARCH 2001;438:1–12CrossRefPubMed Miettinen M, Lasota J. Gastrointestinal stromal tumors–definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. VIRCHOWS ARCH 2001;438:1–12CrossRefPubMed
2.
go back to reference Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. SCIENCE 1998;279:577–580CrossRefPubMed Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. SCIENCE 1998;279:577–580CrossRefPubMed
3.
go back to reference Soreide K, Sandvik OM, Soreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. CANCER EPIDEMIOL 2016;40:39–46CrossRefPubMed Soreide K, Sandvik OM, Soreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. CANCER EPIDEMIOL 2016;40:39–46CrossRefPubMed
4.
go back to reference Xu L, Ma Y, Wang S, et al. Incidence of gastrointestinal stromal tumor in Chinese urban population: A national population-based study. Cancer Med 2021;10:737–744CrossRefPubMed Xu L, Ma Y, Wang S, et al. Incidence of gastrointestinal stromal tumor in Chinese urban population: A national population-based study. Cancer Med 2021;10:737–744CrossRefPubMed
5.
go back to reference Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. HUM PATHOL 2002;33:459–465CrossRefPubMed Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. HUM PATHOL 2002;33:459–465CrossRefPubMed
6.
go back to reference Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. HUM PATHOL 2008;39:1411–1419CrossRefPubMed Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. HUM PATHOL 2008;39:1411–1419CrossRefPubMed
7.
go back to reference Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. SEMIN DIAGN PATHOL 2006;23:70–83CrossRefPubMed Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. SEMIN DIAGN PATHOL 2006;23:70–83CrossRefPubMed
8.
go back to reference Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL 2018;29:v68-v78 Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL 2018;29:v68-v78
9.
go back to reference von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16:536–563CrossRef von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16:536–563CrossRef
10.
go back to reference Sakamoto H, Kitano M, Matsui S, et al. Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUS (with videos). GASTROINTEST ENDOSC 2011;73:227–237CrossRefPubMed Sakamoto H, Kitano M, Matsui S, et al. Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUS (with videos). GASTROINTEST ENDOSC 2011;73:227–237CrossRefPubMed
11.
go back to reference Chen T, Xu L, Dong X, et al. The roles of CT and EUS in the preoperative evaluation of gastric gastrointestinal stromal tumors larger than 2 cm. EUR RADIOL 2019;29:2481–2489CrossRefPubMed Chen T, Xu L, Dong X, et al. The roles of CT and EUS in the preoperative evaluation of gastric gastrointestinal stromal tumors larger than 2 cm. EUR RADIOL 2019;29:2481–2489CrossRefPubMed
12.
go back to reference Tokumoto N, Tanabe K, Misumi T, et al. The usefulness of preoperative 18FDG positron-emission tomography and computed tomography for predicting the malignant potential of gastrointestinal stromal tumors. Dig Surg 2014;31:79–86CrossRefPubMed Tokumoto N, Tanabe K, Misumi T, et al. The usefulness of preoperative 18FDG positron-emission tomography and computed tomography for predicting the malignant potential of gastrointestinal stromal tumors. Dig Surg 2014;31:79–86CrossRefPubMed
13.
go back to reference Yoshikawa K, Shimada M, Kurita N, et al. Efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors. SURG TODAY 2013;43:1162–1167CrossRefPubMed Yoshikawa K, Shimada M, Kurita N, et al. Efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors. SURG TODAY 2013;43:1162–1167CrossRefPubMed
14.
go back to reference Huang P, Li S, Aronow WS, et al. Double contrast-enhanced ultrasonography evaluation of preoperative Lauren classification of advanced gastric carcinoma. ARCH MED SCI 2011;7:287–293CrossRefPubMedPubMedCentral Huang P, Li S, Aronow WS, et al. Double contrast-enhanced ultrasonography evaluation of preoperative Lauren classification of advanced gastric carcinoma. ARCH MED SCI 2011;7:287–293CrossRefPubMedPubMedCentral
15.
go back to reference Shi H, Yu XH, Guo XZ, et al. Double contrast-enhanced two-dimensional and three-dimensional ultrasonography for evaluation of gastric lesions. World J Gastroenterol 2012;18:4136–4144CrossRefPubMedPubMedCentral Shi H, Yu XH, Guo XZ, et al. Double contrast-enhanced two-dimensional and three-dimensional ultrasonography for evaluation of gastric lesions. World J Gastroenterol 2012;18:4136–4144CrossRefPubMedPubMedCentral
16.
go back to reference Shiyan L, Pintong H, Zongmin W, et al. The relationship between enhanced intensity and microvessel density of gastric carcinoma using double contrast-enhanced ultrasonography. ULTRASOUND MED BIOL 2009;35:1086–1091CrossRefPubMed Shiyan L, Pintong H, Zongmin W, et al. The relationship between enhanced intensity and microvessel density of gastric carcinoma using double contrast-enhanced ultrasonography. ULTRASOUND MED BIOL 2009;35:1086–1091CrossRefPubMed
17.
go back to reference Zheng Z, Yu Y, Lu M, et al. Double contrast-enhanced ultrasonography for the preoperative evaluation of gastric cancer: a comparison to endoscopic ultrasonography with respect to histopathology. AM J SURG 2011;202:605–611CrossRefPubMed Zheng Z, Yu Y, Lu M, et al. Double contrast-enhanced ultrasonography for the preoperative evaluation of gastric cancer: a comparison to endoscopic ultrasonography with respect to histopathology. AM J SURG 2011;202:605–611CrossRefPubMed
18.
go back to reference Yu T, Wang X, Zhao Z, et al. Prediction of T stage in gastric carcinoma by enhanced CT and oral contrast-enhanced ultrasonography. WORLD J SURG ONCOL 2015;13:184CrossRefPubMedPubMedCentral Yu T, Wang X, Zhao Z, et al. Prediction of T stage in gastric carcinoma by enhanced CT and oral contrast-enhanced ultrasonography. WORLD J SURG ONCOL 2015;13:184CrossRefPubMedPubMedCentral
19.
go back to reference Ang J, Hu L, Huang PT, et al. Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy. World J Gastroenterol 2012;18:7026–7032CrossRefPubMedPubMedCentral Ang J, Hu L, Huang PT, et al. Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy. World J Gastroenterol 2012;18:7026–7032CrossRefPubMedPubMedCentral
20.
go back to reference Li T, Lu M, Song J, et al. Improvement to ultrasonographical differential diagnosis of gastric lesions: The value of contrast enhanced sonography with gastric distention. PLOS ONE 2017;12:e182332 Li T, Lu M, Song J, et al. Improvement to ultrasonographical differential diagnosis of gastric lesions: The value of contrast enhanced sonography with gastric distention. PLOS ONE 2017;12:e182332
21.
go back to reference Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5 Suppl 2:S1-S29, S30 Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5 Suppl 2:S1-S29, S30
22.
go back to reference Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). CANCER-AM CANCER SOC 2008;112:608–615 Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). CANCER-AM CANCER SOC 2008;112:608–615
23.
go back to reference Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. HUM PATHOL 2008;39:1411–1419CrossRefPubMed Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. HUM PATHOL 2008;39:1411–1419CrossRefPubMed
24.
go back to reference Kim HC, Lee JM, Kim KW, et al. Gastrointestinal stromal tumors of the stomach: CT findings and prediction of malignancy. AJR Am J Roentgenol 2004;183:893–898CrossRefPubMed Kim HC, Lee JM, Kim KW, et al. Gastrointestinal stromal tumors of the stomach: CT findings and prediction of malignancy. AJR Am J Roentgenol 2004;183:893–898CrossRefPubMed
25.
go back to reference Chen TH, Hsu CM, Chu YY, et al. Association of endoscopic ultrasonographic parameters and gastrointestinal stromal tumors (GISTs): can endoscopic ultrasonography be used to screen gastric GISTs for potential malignancy? Scand J Gastroenterol 2016;51:374–377CrossRefPubMed Chen TH, Hsu CM, Chu YY, et al. Association of endoscopic ultrasonographic parameters and gastrointestinal stromal tumors (GISTs): can endoscopic ultrasonography be used to screen gastric GISTs for potential malignancy? Scand J Gastroenterol 2016;51:374–377CrossRefPubMed
26.
go back to reference Kannengiesser K, Mahlke R, Petersen F, et al. Contrast-enhanced harmonic endoscopic ultrasound is able to discriminate benign submucosal lesions from gastrointestinal stromal tumors. Scand J Gastroenterol 2012;47:1515–1520CrossRefPubMed Kannengiesser K, Mahlke R, Petersen F, et al. Contrast-enhanced harmonic endoscopic ultrasound is able to discriminate benign submucosal lesions from gastrointestinal stromal tumors. Scand J Gastroenterol 2012;47:1515–1520CrossRefPubMed
27.
go back to reference Park HY, Jeon SW, Lee HS, et al. Can contrast-enhanced harmonic endosonography predict malignancy risk in gastrointestinal subepithelial tumors? ENDOSC ULTRASOUND 2016;5:384–389CrossRefPubMedPubMedCentral Park HY, Jeon SW, Lee HS, et al. Can contrast-enhanced harmonic endosonography predict malignancy risk in gastrointestinal subepithelial tumors? ENDOSC ULTRASOUND 2016;5:384–389CrossRefPubMedPubMedCentral
28.
go back to reference Kamata K, Takenaka M, Kitano M, et al. Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of submucosal tumors of the upper gastrointestinal tract. J Gastroenterol Hepatol 2017;32:1686–1692CrossRefPubMed Kamata K, Takenaka M, Kitano M, et al. Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of submucosal tumors of the upper gastrointestinal tract. J Gastroenterol Hepatol 2017;32:1686–1692CrossRefPubMed
29.
go back to reference Cho IR, Park JC, Roh YH, et al. Noninvasive prediction model for diagnosing gastrointestinal stromal tumors using contrast-enhanced harmonic endoscopic ultrasound. Dig Liver Dis 2019;51:985–992CrossRefPubMed Cho IR, Park JC, Roh YH, et al. Noninvasive prediction model for diagnosing gastrointestinal stromal tumors using contrast-enhanced harmonic endoscopic ultrasound. Dig Liver Dis 2019;51:985–992CrossRefPubMed
30.
go back to reference Fukuta N, Kitano M, Maekawa K, Chikugo T, Kudo M. Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US. J GASTROENTEROL 2005;40:247–255CrossRefPubMed Fukuta N, Kitano M, Maekawa K, Chikugo T, Kudo M. Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US. J GASTROENTEROL 2005;40:247–255CrossRefPubMed
31.
go back to reference Chen Z, Yang J, Sun J, Wang P. Gastric gastrointestinal stromal tumours (2–5 cm): Correlation of CT features with malignancy and differential diagnosis. EUR J RADIOL 2020;123:108783CrossRefPubMed Chen Z, Yang J, Sun J, Wang P. Gastric gastrointestinal stromal tumours (2–5 cm): Correlation of CT features with malignancy and differential diagnosis. EUR J RADIOL 2020;123:108783CrossRefPubMed
32.
go back to reference Li C, Fu W, Huang L, et al. A CT-based nomogram for predicting the malignant potential of primary gastric gastrointestinal stromal tumors preoperatively. Abdom Radiol (NY) 2021 Li C, Fu W, Huang L, et al. A CT-based nomogram for predicting the malignant potential of primary gastric gastrointestinal stromal tumors preoperatively. Abdom Radiol (NY) 2021
33.
go back to reference Chen T, Ning Z, Xu L, et al. Radiomics nomogram for predicting the malignant potential of gastrointestinal stromal tumours preoperatively. EUR RADIOL 2019;29:1074–1082CrossRefPubMed Chen T, Ning Z, Xu L, et al. Radiomics nomogram for predicting the malignant potential of gastrointestinal stromal tumours preoperatively. EUR RADIOL 2019;29:1074–1082CrossRefPubMed
Metadata
Title
An ultrasound based method for predicting the malignant potential of primary gastrointestinal stromal tumors preoperatively
Authors
Tingting Li
Juan Li
ZiYue Hu
Man Lu
Publication date
08-06-2024
Publisher
Springer US
Published in
Abdominal Radiology
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-024-04341-5
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare